Galapagos NV (BSP:G1LP34) Total Equity : R$17,106 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Galapagos NV Total Equity?

Galapagos NV's total equity for the quarter that ended in Mar. 2025 was R$17,106 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Galapagos NV Total Equity Historical Data

The historical data trend for Galapagos NV's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Total Equity Chart

Galapagos NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Equity

Get a 7-Day Free Trial

16,713.11

16,890.34

14,036.04

14,937.53

18,507.04

Galapagos NV Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Equity	Get a 7-Day Free Trial															15,670.18	16,873.13	17,594.16	18,507.04	17,105.57

Galapagos NV Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Galapagos NV's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2024 )	-	Total Liabilities(Q: Dec. 2024 )
	=	26420.965	-	7913.923
	=	18,507

Galapagos NV's Total Equity for the quarter that ended in Mar. 2025 is calculated as

Total Equity	=	Total Assets(Q: Mar. 2025 )	-	Total Liabilities(Q: Mar. 2025 )
	=	25036.505	-	7930.939
	=	17,106

Galapagos NV Total Equity Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (BSP:G1LP34) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

GLPGF:USA GLPG:USA GLPG:Netherlands GLPGa:UK 0JXZ:UK GXEA:Germany GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Galapagos NV Headlines

No Headlines